PF 04217903 mesylate

Biological Activity for PF 04217903 mesylate

Technical Data for PF 04217903 mesylate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for PF 04217903 mesylate

References for PF 04217903 mesylate

References are publications that support the biological activity of the product.

• Khelwatty S, Essapen S, Seddon A, Fan Z, Modjtahedi H Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer, 2015;113(7):1010-9. 2015 PMID: 26372697
• Eder et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin.Cancer Res., 2009;15:2207 PMID: 19318488
• Timofeevski et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry, 2009;48:5339 PMID: 19459657
• Underiner et al. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med.Chem., 2010;10:7 PMID: 20015007
• Cui et al. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6- J.Med.Chem., 2012;55:8091 PMID: 22924734